Impact of Underweight after Treatment on Prognosis of Advanced-Stage Ovarian Cancer

Table 3

Clinicopathologic factors affecting progression-free and overall survivals in 29 patients who showed underweight after treatment.

Characteristics	Univariate			Multivariate
	HR	95% CI	𝑃 value	Adjusted HR	95% CI	𝑃 value
Progression-free survival
≥53 years	1.91	0.79–4.63	0.15	—	—	—
Stage IV disease	1.88	0.68–5.18	0.23	4.89	1.14–20.94	0.03
Grade 3 disease	0.94	0.33–2.70	0.91	—	—	—
Nonserous histology	2.99	1.13–7.90	0.03	—	—	—
No neoadjuvant chemotherapy	1.54	0.51–4.64	0.45	—	—	—
≤6 cycles of adjuvant chemotherapy	1.10	0.40–3.01	0.86	—	—	—
Suboptimal debulking surgery	3.89	1.55–9.74	<0.01	10.04	1.48–68.13	0.02
Weight loss ≥10%	4.07	1.55–10.64	<0.01	6.90	1.51–31.54	0.01
Overall survival
≥53 years	2.07	0.62–6.92	0.24	—	—	—
Stage IV disease	1.92	0.40–9.25	0.42	11.9	1.00–141.1	0.05
Grade 3 disease	0.77	0.17–3.47	0.73	—	—	—
Nonserous histology	2.58	0.73–9.15	0.14	—	—	—
No neoadjuvant chemotherapy	1.27	0.27–6.02	0.77	—	—	—
≤6 cycles of adjuvant chemotherapy	3.84	0.78–18.91	0.10	—	—	—
Suboptimal debulking surgery	2.64	0.88–7.91	0.08	—	—	—
Weight loss ≥10%	12.81	2.54–64.65	<0.01	15.27	1.42–164.5	0.02